Derivation of clinical-grade human embryonic stem cells.

Embryonic stem cells proliferate in vitro while maintaining an undifferentiated state, and are capable of differentiating into most cell types under appropriate conditions. These properties imply great potential in the treatment of various diseases and disabilities. In fact, the first clinical trials with hESC for treating spinal cord injuries will begin next year. However, therapeutic application of human embryonic stem cell derivatives is compromised by the exposure of existing lines to animal and human components, with the subsequent risk of contamination with retroviruses and other pathogens, which can be transmitted to patients. The scientific community is striving to avoid the use of xenogeneic or allogeneic components in the process of derivation new hESC lines. This review summarizes attempts that have been made to avoid these contaminants and the breakthroughs achieved in the derivation of clinical-grade hESC that could be used for therapeutic purposes.